Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Waldenstrom's Macroglobulinemia (WM)”

19 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 19 results

Early research (Phase 1)Ended earlyNCT01078974
What this trial is testing

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

Who this might be right for
Waldenstrom's Macroglobulinemia
Steven P. Treon, MD, PhD 7
Testing effectiveness (Phase 2)Study completedNCT00936611
What this trial is testing

LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

Who this might be right for
Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute 39
Testing effectiveness (Phase 2)Study completedNCT00003416
What this trial is testing

S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia

Who this might be right for
Lymphoma
SWOG Cancer Research Network 9
Early research (Phase 1)Study completedNCT04274738
What this trial is testing

Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Who this might be right for
Waldenstrom's Macroglobulinemia
X4 Pharmaceuticals 16
Testing effectiveness (Phase 2)Study completedNCT04062448
What this trial is testing

Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Who this might be right for
Waldenstrom Macroglobulinemia
Janssen Pharmaceutical K.K. 16
Testing effectiveness (Phase 2)Study completedNCT01470196
What this trial is testing

Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia

Who this might be right for
Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute 31
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07464210
What this trial is testing

Nemtabrutinib, Bortezomib, and Rituximab for WM

Who this might be right for
Waldenstrom Macroglobulinemia
Seoul National University Hospital 19
Testing effectiveness (Phase 2)Study completedNCT04440059
What this trial is testing

ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

Who this might be right for
Waldenstrom's Macroglobulinemia RecurrentWaldenstrom's Macroglobulinemia Refractory
Beijing InnoCare Pharma Tech Co., Ltd. 47
Testing effectiveness (Phase 2)Looking for participantsNCT04840602
What this trial is testing

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Who this might be right for
Lymphoplasmacytic LymphomaWaldenstrom Macroglobulinemia
National Cancer Institute (NCI) 92
Testing effectiveness (Phase 2)Study completedNCT00005609
What this trial is testing

Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

Who this might be right for
Lymphoma
Eastern Cooperative Oncology Group
Testing effectiveness (Phase 2)Study completedNCT00422656
What this trial is testing

Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Who this might be right for
Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute 37
Post-approval studies (Phase 4)Study completedNCT04042376
What this trial is testing

Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

Who this might be right for
Waldenstrom Macroglobulinemia
Janssen Research & Development, LLC 17
Testing effectiveness (Phase 2)Active Not RecruitingNCT04624906
What this trial is testing

Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

Who this might be right for
Waldenstrom Macroglobulinemia
Sunnybrook Health Sciences Centre 63
Not applicableStudy completedNCT00919139
What this trial is testing

S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.

Who this might be right for
Multiple MyelomaSmoldering MyelomaWaldenstrom's Macroglobulinemia+2 more
SWOG Cancer Research Network 190
Testing effectiveness (Phase 2)Study completedNCT01592981
What this trial is testing

Randomised Trial in Waldenstrom's Macroglobulinaemia

Who this might be right for
Waldenstrom's Macroglobulinaemia
University College, London 60
Early research (Phase 1)Study completedNCT02071888
What this trial is testing

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Who this might be right for
Non-Hodgkin's Lymphoma (NHL)Multiple MyelomaWaldenstrom's Macroglobulinemia (WM)+2 more
Calithera Biosciences, Inc 25
Testing effectiveness (Phase 2)Study completedNCT00976248
What this trial is testing

Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia

Who this might be right for
Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute 33
Early research (Phase 1)Looking for participantsNCT06980116
What this trial is testing

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Relapsed or Refractory B-cell MalignanciesChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Follicular Lymphoma (FL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 85
Testing effectiveness (Phase 2)Study completedNCT00422799
What this trial is testing

Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

Who this might be right for
Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute 63